Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Multidisciplinary Adrenal Program, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Front Endocrinol (Lausanne). 2024 Feb 27;14:1280603. doi: 10.3389/fendo.2023.1280603. eCollection 2023.
The dramatic rise in opioid use over the last two decades has led to a surge in their harmful health effects. Lesser known among clinicians is the impact of opioids on the endocrine system, especially with regard to cortisol. Opioids can suppress the hypothalamus-pituitary-adrenal (HPA) axis and may result in clinically significant adrenal insufficiency, especially in those treated at higher doses and for a longer time. A high clinical suspicion is necessary in this population for early diagnosis of opioid-induced adrenal insufficiency (OAI). Diagnosis of OAI is challenging, as the symptoms are often vague and overlap with those due to opioid use or the underlying pain disorder. Traditional assays to diagnose adrenal insufficiency have not been widely studied in this population, and more investigation is needed to determine how opioids might affect assay results. Once a diagnosis of adrenal insufficiency has been made, glucocorticoid replacement in the form of hydrocortisone is likely the mainstay of treatment, and effort should be made to taper down opioids where possible. Cortisol levels should be retested periodically, with the goal of stopping glucocorticoid replacement once the HPA axis has recovered. In this review, we provide context for diagnostic challenges in OAI, suggest diagnostic tools for this population based on available data, and offer recommendations for the management of this disorder. There is a paucity of literature in this field; given the widespread use of opioids in the general population, more investigation into the effects of opioids on the HPA axis is sorely needed.
在过去的二十年中,阿片类药物的使用急剧增加,导致其对健康的危害也急剧增加。在临床医生中鲜为人知的是阿片类药物对内分泌系统的影响,尤其是对皮质醇的影响。阿片类药物可以抑制下丘脑-垂体-肾上腺(HPA)轴,并且可能导致临床上显著的肾上腺功能不全,尤其是在接受更高剂量和更长时间治疗的患者中。在这些人群中,需要高度的临床怀疑以早期诊断阿片类药物引起的肾上腺功能不全(OAI)。OAI 的诊断具有挑战性,因为其症状通常较为模糊,与阿片类药物使用或潜在疼痛障碍引起的症状相重叠。传统的诊断肾上腺功能不全的检测方法在该人群中尚未得到广泛研究,需要进一步研究以确定阿片类药物如何影响检测结果。一旦诊断出肾上腺功能不全,以氢化可的松形式进行糖皮质激素替代治疗可能是主要治疗方法,并且应尽可能减少阿片类药物的用量。应定期检测皮质醇水平,一旦 HPA 轴恢复,目标是停止糖皮质激素替代治疗。在本综述中,我们提供了 OAI 诊断挑战的背景信息,根据现有数据为该人群提出了诊断工具,并为该疾病的管理提供了建议。该领域的文献很少;鉴于阿片类药物在普通人群中的广泛使用,迫切需要更多地研究阿片类药物对 HPA 轴的影响。